OS for patients treated with BV-DTIC (part B) or BV-nivolumab (part D) (full analysis set). (A) For patients treated with BV-DTIC, mOS has not been reached yet (95% CI, 53.36-not estimable) at a median follow-up of 63.6 months, and there were 9 OS events among 22 patients. (B) For patients treated with BV-nivolumab, mOS has not been reached yet (95% CI, not estimable-not estimable) at a median follow-up of 51.6 months, and 4 OS events occurred among 21 patients. Censored patients are denoted by hash marks.